Download Files:
Cap-dependent endonuclease-IN-2
Products Details
Product Description
– Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28)[1].
Web ID
– HY-143743
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C30H24FN3O7S
References
– [1]Changhua Tang, et al. Influenza virus replication inhibitors and their uses. Patent WO2019052565A1.
CAS Number
– 2303917-78-2
Molecular Weight
– 589.59
SMILES
– COC(OCOC1=C2N(C=CC1=O)N([C@@]3([H])N(CCOC3)C2=O)[C@@]4([H])C5=CC=C(F)C=C5C6=C(SC=C6)C7=CC=CC=C74)=O
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– Influenza Virus
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.